Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

36.90
-1.2000-3.15%
Post-market: 36.38-0.5200-1.41%17:08 EDT
Volume:1.03M
Turnover:38.64M
Market Cap:2.90B
PE:-8.50
High:38.59
Open:38.39
Low:36.84
Close:38.10
52wk High:45.14
52wk Low:22.10
Shares:78.49M
Float Shares:73.02M
Volume Ratio:1.61
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:4.05
PE(LYR):-9.46

Loading ...

Celldex CFO Sam Martin to Retire in 2027, Stays Through March 2027 Transition

Reuters
·
Jul 16

Celldex Announces Planned Transition of Chief Financial Officer

THOMSON REUTERS
·
Jul 16

Celldex Therapeutics - Celldx CFO SAM Martin Plans to Retire in 2027

THOMSON REUTERS
·
Jul 16

Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?

Simply Wall St.
·
Jul 06

Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus

Simply Wall St.
·
Jul 02

Celldex Therapeutics Shareholders Approve 3,400,000-share Increase to 2021 Equity Plan at Annual Meeting

Reuters
·
Jun 26

Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data

Simply Wall St.
·
Jun 20

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

Why Celldex Therapeutics (CLDX) Is Up 12.2% After CSU Drug Data Suggest Disease Modification Potential

Simply Wall St.
·
Jun 18

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 15

Celldex Therapeutics Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

Celldex presents long-term results from Phase 2 study of barzolvolimab

TIPRANKS
·
Jun 15

Celldex presents first-in-human results for CDX-622

TIPRANKS
·
Jun 15

Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study

Reuters
·
Jun 14

Celldex says Phase 2 barzolvolimab data show sustained off-treatment angioedema improvement in CSU patients

Reuters
·
Jun 14

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained off-Treatment Improvement in Angioedema in Patients With Csu at the European Academy of Allergy and Clinical Immunology Annual Meeting

THOMSON REUTERS
·
Jun 14

Celldex Therapeutics - Barzolvolimab Meets Primary Efficacy Endpoint in Phase 2 Csu Study

THOMSON REUTERS
·
Jun 14

Celldex reports positive Phase 1 results for bispecific antibody CDX-622 in healthy participants

Reuters
·
Jun 14

Celldex Presents Positive First-in-Human Results From Phase 1 Study of Novel Bispecific Cdx-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

THOMSON REUTERS
·
Jun 14

Celldex to present barzolvolimab, CDX-622 data at EAACI annual congress

Reuters
·
Jun 11